Improving Local Tumor Control by Combining Vascular Targeting Drugs, Mild Hyperthermia and Radiation

References

• Field SB, Bleehen NM. Hyperthermia in the treatment of cancer. Cancer Treat Rev 1979; 6: 63–94.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Overgaard J. Thermal radiosensitization in animal tumors: the potential for therapeutic gain. In: Urano M, Douple E, eds. Hyperthermia and oncology, vol. 2. Utrecht: VSP, 1989: 113–45.
   Google Scholar
• Overgaard J, Gonzalez Gonzalez D, Hulshof MCCM, et al. Hyperthermia as an adjuvant to radiation therapy of recur-rent or metastatic malignant melanoma. A multicentre ran-domized trial by the European Society for Hyperthermic Oncology. Int J Hyperthermia 1996; 12: 3–20.
   PubMed Web of Science ®Google Scholar
• Vernon CC, Hand JW, Field SB, et al. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer results from five randomized controlled trials. Int J Radiat Oncol Biol Phys 1996; 35: 731–44.
   PubMed Web of Science ®Google Scholar
• Prosnitz LR, Maguire P, Anderson JM, et al. The treatment of high-grade soft tissue sarcomas with preoperative thermoradiotherapy. Int J Radiat Oncol Biol Phys 1999; 45: 941–9.
   PubMed Web of Science ®Google Scholar
• Oleson JR. Hyperthermia from the clinic to the laboratory: a hypothesis. Int J Hyperthermia 1995; 11: 315–22.
   PubMed Web of Science ®Google Scholar
• Jain RK, Grantham FH, Gullino PM. Blood flow and heat transfer in Walker 256 mammary carcinoma. J Natl Cancer Inst 1979; 62: 927–33.
   Google Scholar
• Patterson J, Strang R. The role of blood flow in hyperther-mia. Int J Radiat Oncol Biol Phys 1979; 5: 235–41.
   PubMed Web of Science ®Google Scholar
• Vaupel P. Oxygen supply to malignant tissues. In: Peterson HI, ed. Tumor blood circulation: angiogenesis, vascular mor-phology and blood flow of experimental and human tumors.
   Google Scholar
• Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumor pH to the treatment of malignant disease. Radiother Oncol 1984; 2: 343–66.
   Google Scholar
• Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of maligant cells in vitro. Radiol 1977; 123: 511–4.
   PubMed Web of Science ®Google Scholar
• Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979; 39: 966–72.
   Google Scholar
• Overgaard J, Nielsen OS. The role of tissue environmental factors on the kinetics and morphology of tumor cells exposed to hyperthermia. Ann New York Acad Sci 1980; 335: 254–80.
   PubMedGoogle Scholar
• Suit HD. Hyperthermia in the treatment of tumors. In: Proc Int Symp cancer therapy by hyperthermia and radiation, Washington, 28–30 April. American College of Radiology, 1975: 107–14.
   Google Scholar
• Hill SA, Denekamp J. The effect of vascular occlusion on the thermal sensitization of a mouse tumor. Br J Radiol 1978; 51: 997–1002.
   PubMed Web of Science ®Google Scholar
• Wallen CA, Colby TV, Stewart JR. Cell kill and tumor control after heat treatment with and without vascular occlu-sion in RIF-1 tumors. Radiat Res 1986; 106: 215–23.
   Google Scholar
• Crile G. The effects of heat and radiation on cancers im-planted on the feet of mice. Cancer Res 1963; 23: 372–80.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Christensen KL, Overgaard J. Hydralazine-in-duced enhancement of hyperthermic damage in a C3H mam-
   Google Scholar
• Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In:
   Google Scholar
• Kalmus J, Okunieff P, Vaupel P. Dose-dependent effects of hydralazine on microcirculatory function and hyperthermic response of murine FSaII tumors. Cancer Res 1990; 50: 15–9.
   Google Scholar
• Honess DJ, Hu DE, Bleehen NM. A study of the mechanism of hydralazine enhancement of thermal damage in the KHT tumour. Int J Hyperthermia 1991; 7: 667–79.
   Google Scholar
• Evelhoch JL, Bissery MC, Chabot GG, et al. Flavone acetic acid (NSC 347512)-induced modulation of murine tumor physiology monitored by in vivo nuclear magnetic resonance spectroscopy. Cancer Res 1988; 48: 4749–55.
   PubMed Web of Science ®Google Scholar
• Bibby MC, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: a possible compo-nent of therapy. J Natl Cancer Inst 1989; 81: 216–20.
   PubMed Web of Science ®Google Scholar
• Hill SA, Williams KB, Denekamp J. Vascular collapse after flavone acetic acid: a possible mechanism of its anti-tumour action. Eur J Cancer Clin Oncol 1989; 25: 1419–24.
   Google Scholar
• Zwi LJ, Baugley BC, Gavin JB, Wilson WR. Blood flow as a major deteminant in the antitumour action of flavone acetic acid. J Natl Cancer Inst 1989; 81: 1005–13.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Chaplin DJ, Overgaard J. The effect of combining flavone acetic acid and hyperthermia on the growth of a C3H mammary carcinoma in vivo. Int J Radiat Biol 1991; 60: 385–8.
   Google Scholar
• Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperther-mia. Int J Hyperthermia 1996; 12: 779–89.
   PubMed Web of Science ®Google Scholar
• Corbett TH, Bissery MC, Wozniak A, et al. Activity of flavone acetic acid (NSC-347512) against solid tumors of mice. Invest New Drugs 1986; 4: 207–20.
   PubMed Web of Science ®Google Scholar
• Plowman J, Narayanan VL, Dykes D, et al. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice. Cancer Treat Rep 1986; 70: 631–5.
   PubMedGoogle Scholar
• Bibby MC, Double JA, Phillips RM, Loadman PM. Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). Br J Cancer 1987; 55: 159–63.
   PubMed Web of Science ®Google Scholar
• Smith GP, Calveley SB, Smith MJ, Baguley BC. Flavone acetic acid (NSC 347512) induced haemorrhagic necrosis of mouse colon 26 and 28 tumours. Eur J Cancer Clin Oncol 1987; 23: 1209–11.
   PubMedGoogle Scholar
• Finlay GT, Smith GP, Fray LM, Baguley BC. Effect of flavone acetic acid on Lewis lung carcinoma: evidence for an indirect effect. J Natl Cancer Inst 1988; 80: 241–5.
   PubMed Web of Science ®Google Scholar
• Zwi LJ, Baguley BC, Gavin JB, Wilson WR. The use of vascularized spheroids to investigate the action of flavone acetic acid on tumour blood vessels. Br J Cancer 1990; 62: 231–7.
   PubMed Web of Science ®Google Scholar
• Kerr DJ, Maughan T, Newlands E, et al. Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma. Br J Cancer 1989; 60: 104–6.
   PubMed Web of Science ®Google Scholar
• Kaye SB, Clavel M, Dodion P, et al. Phase II trials with flavone acetic acid (NCS-347512, LM975) in patients with advanced carcinoma of the breast, colon, head and neck and melanoma. Invest New Drugs (Suppl) 1990; 8 (1): S95–9.
   Google Scholar
• Sakaguchi Y, Maehara Y, Baba H, Kusumoto T, Sugimachi K, Newman RA. Flavone acetic acid increases the antitumor effect of hyperthermia in mice. Cancer Res 1992; 52: 3306–9.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Simultaneous and sequential hyperthermia and radiation treatment of an experimental tumor and its sur-rounding normal tissue in vivo. Int J Radiat Oncol Biol Phys 1980; 6: 1507–17.
   PubMed Web of Science ®Google Scholar
• Lindegaard JC, Overgaard J. Factors of importance for the development of the step-down heating effect in a C3H mam-mary carcinoma in vivo. Int J Hyperthermia 1987; 3: 79–91.
   PubMed Web of Science ®Google Scholar
• Voorhees WD, Babbs CF. Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs. Eur J Cancer Clin Oncol 1982; 19: 1027–33.
   Google Scholar
• Dewhirst MW, Prescott DM, Clegg S, et al. The use of hydralazine to manipulate tumour temperatures during hyper-thermia. Int J Hyperthermia 1990; 6: 971–83.
   PubMed Web of Science ®Google Scholar
• Overgaard J. Rationale and problems in the design of clinical trials. In: Overgaard J, ed. Hyperthermic Oncology 1984, vol. 2. London: Taylor and Francis, 1985: 325–38.
   Google Scholar
• Mahadevan V, Malik STA, Meager A, Fiers W, Lewis GP, Hart JR. Role of tumor necrosis factor in flavone acetic acid-induced tumor vasculature shutdown. Cancer Res 1990; 50: 5537–42.
   PubMed Web of Science ®Google Scholar
• Ching L-M, Joseph WR, Crosier KE, Baguley BC. Induction of tumor necrosis factor-a messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid. (NSC 540488). Cancer Res 1994; 54: 870–2.
   Google Scholar
• Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. hit J Cancer 1995; 63: 119–23.
   Google Scholar
• Baguley BC, Holdaway KM, Thomsen LL, Zhuang L, Zwi U. Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur J Cancer 1991; 27: 482–7.
   Google Scholar
• Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivas-cular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by the combination with 5-hydroxytryptamine and bioreduc-tive drugs. Br J Cancer 1998; 78: 439–45.
   PubMed Web of Science ®Google Scholar
• Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phos-phate. Anticancer Res 1999; 19: 189–96.
   Google Scholar
• Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999; 80 (Suppl) (1): 57–64.
   Google Scholar
• Laws AL, Matthew AM, Double JA, Bibby MC. Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-ace-tic acid. Br J Cancer 1995; 71: 1204–9.
   PubMed Web of Science ®Google Scholar
• Dark GD, Hill SA, Prise YE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 1997; 57: 1829–34.
   PubMed Web of Science ®Google Scholar
• Li L, Rojiani A, Siemann DW. Targeting the tumor vascula-ture with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int .1- Radiat Oncol Biol Phys 1998; 42: 899 —903.
   Google Scholar
• Wilson WW, Li AE, Cowan D, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int .1- Radiat Oncol Biol Phys 1998; 42: 905–8.
   PubMed Web of Science ®Google Scholar